Wang Yaqi, Wang Xing, Yan Shi, Yang Yue, Wu Nan
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Zhongguo Fei Ai Za Zhi. 2017 May 20;20(5):352-360. doi: 10.3779/j.issn.1009-3419.2017.05.09.
Background and objective Lung cancer is the leading form of cancer in terms of both incidence and cancer-related deaths. For patients with resectable IIIa/N2 non-small cell lung cancer (NSCLC), guidelines in and abroad recommend multidisciplinary team treatment, including surgery and chemotherapy, radiotherapy or other comprehensive treatment. Newly published evidences prove that neoadjuvant therapy can improve outcomes of NSCLC patients significantly, with advangtages in tolerability and compliance medication. Neoadjuvant therapy has been adopted mainly in locally advanced NSCLC, especially in stages IIIa/N2 patients, and chemotherapy of 2-4 cycles has become the basic pattern. Neoadjuvant therapy does not increase the concomitant complications of chemotherapy and surgery. However, challenges still exist in determining subsequent surgical timing, approach and extent of resection.
背景与目的 肺癌在发病率和癌症相关死亡方面都是主要的癌症形式。对于可切除的Ⅲa/N2期非小细胞肺癌（NSCLC）患者，国内外指南推荐多学科团队治疗，包括手术及化疗、放疗或其他综合治疗。新发表的证据证明新辅助治疗可显著改善NSCLC患者的预后，在耐受性和药物依从性方面具有优势。新辅助治疗主要应用于局部晚期NSCLC，尤其是Ⅲa/N2期患者，2-4周期化疗已成为基本模式。新辅助治疗不会增加化疗和手术的伴随并发症。然而，在确定后续手术时机、手术方式及切除范围方面仍存在挑战。
